Our data demonstrate that inhibition of HDAC5 effectively reverses TTN-silencing-induced gene dysregulation, thereby identifying HDAC5 as a promising therapeutic target in TTN-deficient related cardiomyopathy. This evidence concerns the gene TTN and cardiomyopathy.